Physician profile
Jade Lee
NPI 1891153235
$1,331.78
in general payments reported to CMS, 2019-2025
10 companies · $695 in 2025
The $695 reported for 2025 was more than what 81% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $637 · 2025: $695.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,332.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,331.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $350.10 | 2025 | Breztri, Fasenra |
| Alnylam Pharmaceuticals INC. | $312.51 | 2024-2025 | Onpattro, Oxlumo, Givlaari |
| Regeneron Healthcare Solutions, INC. | $121.69 | 2024 | Dupixent |
| Coloplast Corp | $119.10 | 2024 | |
| Phathom Pharmaceuticals, INC. | $116.22 | 2024 | Voquezna |
| Gilead Sciences, INC. | $109.59 | 2025 | Yeztugo |
| Pfizer INC. | $102.62 | 2024 | |
| Cipher Pharmaceuticals US LLC | $55.29 | 2025 | Natroba, Spinosad |
| Abbott Laboratories | $23.20 | 2025 | Amplatzer Amulet |
| Tonix Medicines, INC. | $21.46 | 2025 | Tonmya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jade Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.